Abstract. We administered growth hormone (GH) to 40 patients with achondroplasia, 9 of whom were suspected to have insufficient GH secretion. The patients received 0.5 or 1.0IU/kg/week recombinant human GH. At the end of the first year, the annual height gain was significantly increased compared to before treatment. There was no difference between patients with normal or insufficient GH secretion in the annual height gain, either before or during GH treatment. The annual height gain during treatment of patients treated with GH at 0.5IU/kg/week did not differ from those treated with 1.0IU/kg/week. The annual height gain before and during GH treatment of patients in the pubertal stage was less than those in the prepubertal stage. Although the annual height gain in the second year of GH treatment was less than in the first year, it was still greater than before GH treatment. The lower limb length to height ratio was significantly increased by GH treatment.
Introduction
The main concern of patients with achondroplasia is that their final height will be extremely short 1). Although the majority of patients show delayed development, particularly in motor skills, during infancy and early childhood 2), compensation is observed in almost all, with no residual psychomotor disorder in adulthood.
For aesthetic, psychological and sociologic reasons, their extremely short stature with relative shortening of the limbs is their most serious anxiety. Previous studies of the growth plate in achondroplasia have revealed abnormal enchondral ossification 3)4), but its specific mechanism remains unclear.
As there is presently no effective pharmacological therapy which normalizes bone growth in achondroplasia, surgical limb lengthening procedures are the only established therapy for the short stature in patients with this disease. However, as surgical limb lengthening procedures require long-term hospitalization and may result in serious complications, such as postoperative infection and fractures or deviation of the bone axis 5), the number of patients who can take advantage of this therapy is limited.
The use of growth hormone (GH) extracted from human pituitary glands was formerly restricted to short children with a demon- There are some recent reports describing the beneficial effects of GH therapy in hypochondroplasia 8), and some investigators have also examined the effectiveness of GH administration in achondroplasia 9)10)11). GH therapy before surgical limb lengthening procedures sometimes can markedly increase the final height.
Measurement of GH secretion in patients with achondroplasia
The subjects were 40 patients (15 males and 25 females) with achondroplasia whose ages ranged from 3 to 13 years. Their average age was 6 years, and seven patients were At the end of the second year of GH therapy, although the annual height gain was lower than in the first year, it was still greater than before GH therapy (Fig.3) .
The ratio of lower limb length to height was significantly increased after GH therapy (Fig.4) I levels of the patients with subnormal GH response to provocation tests were lower than those with normal GH secretion, and that the majority of the patients showed delayed bone age. However, there was no definite relationship between the severity of delayed development or of hydrocephalus, and GH secretion. There were also no significant differences between the patients with normal or insufficient GH secretion in the responses to GH administration. hood. Although the annual height gain during the first year of GH treatment of patients treated with GH at 0.5IU/kg/week did not differ from those treated at 1.0IU/kg/week, longer term follow-up is necessary to determine the effect of the two GH dosage. Further study is essential to establish the most effective GH administration regimen, as the response of a child to GH is determined by the pretreatment growth velocity, the dose of GH used, the frequency of administration, and the condition being treated 14). Although we did not observe any adverse effects, Okabe et al. reported the case of one patient with achondroplasia who showed atlantoaxial dislocation and neurological complications during GH therapy 9). Careful follow-up with not only routine laboratory tests, including thyroid function and glucose tolerance tests, but also orthopedic and neurological exminations, is required.
Conclusions
We found GH treatment for two years to increase the stature and improve body proportions in achondroplasia, with no adverse effects.
The most effective GH treatment regimen
